• This launch is part of the group’s strategic plan and its objective to consolidate and develop a distinctive portfolio based on quality and innovation.

• Women, on average, spend 25% more of their lives in poor health compared to men, mainly due to the lack of developments and treatments specifically targeted at them.

Madrid, March 18, 2025 – Labiana, the pharmaceutical laboratory specialized in both animal and human health listed on BME Growth, is expanding its business in the human health sector with the launch of a product line dedicated entirely to the well-being and care of women.

Labiana, which specializes in the development and manufacturing of its own products and for third parties (CDMO), frames this launch within the group’s strategic plan and one of its main objectives, which is to consolidate and develop a distinctive portfolio based on two key pillars: the quality of its products and innovation, such as in its dosage form. In this way, it further diversifies its activity and aligns with the key focuses of this plan, positioning Labiana as a leader in the development of complex products. On one hand, it strengthens its commitment to women’s health, while on the other, it focuses on niche solutions that address unmet needs.

Since the launch of Fosfomycin Trometamol, Labiana has positioned itself in 60 international markets for the treatment of recurrent urinary infections in women. For this reason, one of the main strategic pillars of its business plan is to increase the offering of its women’s health portfolio with its current partners. Furthermore, women’s health is one of the markets with the highest growth potential in the pharmaceutical industry, considering data such as the fact that women, on average, spend 25% more of their lives in poor health compared to men, mainly due to the lack of developments and treatments specifically targeted at them, according to a…     estudio de Mckinsey.

This new line, led by Labiana’s Business Development team, anticipates the addition of a new product each year. In this way, the portfolio will consist of antifungal solutions, dietary supplements, and cosmetic products specifically designed for the well-being of women and pregnant women, some of which are already in advanced stages of development and will be available in pharmacies.

The main market for the distribution of these products will be Europe, where Labiana’s Fosfomycin is the leading prescription antibiotic for urinary tract infections. However, its commercialization will be global, with a priority in regions where generics have higher penetration, such as Latin America and the Middle East.

José Manuel García Plaza, head of the human health business at Labiana, highlights: “The launch of this product line is not only key to our strategic plan and the objective of expanding our portfolio with innovative, distinctive, and high-quality products, but it also forms part of an even greater ambition: to extend this health line into a broader urogenital health area, which in the future will include both women’s and men’s health.”